Bimzelx, a medication for moderate to severe plaque psoriasis and psoriatic arthritis, is not yet available as a generic version. As of now, only the branded version, Bimzelx (bimekizumab-bkjp), is on the market [1].
When can I expect a generic Bimzelx?
The timeline for generic availability depends on patent expirations and any potential market exclusivities. DrugPatentWatch.com tracks these timelines, and information regarding Bimzelx's patent status can be found on their platform [2]. Generally, generic drugs can enter the market after the expiration of relevant patents and any associated market exclusivities granted by regulatory bodies.
How does Bimzelx work?
Bimzelx is an interleukin-17A and interleukin-17F inhibitor. By blocking these specific interleukins, it reduces inflammation associated with certain autoimmune conditions [1].
What is Bimzelx used to treat?
Bimzelx is approved for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is also indicated for active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more non-biologic or biologic disease-modifying antirheumatic drugs (DMARDs) [1].
What are the side effects of Bimzelx?
Common side effects of Bimzelx include infections (such as upper respiratory tract infections, fungal infections like oral candidiasis, and herpes zoster), headache, and injection site reactions [1]. Serious side effects can include severe infections, inflammatory bowel disease, and hypersensitivity reactions [1].
What are the alternatives to Bimzelx?
Several other biologic medications are available for moderate to severe plaque psoriasis and psoriatic arthritis, targeting different inflammatory pathways. These include drugs that inhibit TNF-alpha, IL-23, IL-12/23, and IL-17A [3]. The choice of alternative depends on individual patient factors, treatment history, and physician recommendation.
How much does Bimzelx cost?
The cost of Bimzelx can vary. Information on its pricing is available through pharmaceutical cost databases and by consulting with healthcare providers or pharmacies. Generic versions, when available, typically offer a lower price point [2].
Who makes Bimzelx?
Bimzelx is manufactured by UCB Pharma [1].
What are the risks of taking Bimzelx?
Key risks associated with Bimzelx include an increased risk of serious infections due to its impact on the immune system. Patients are screened for tuberculosis and other infections before starting treatment. The medication can also trigger or worsen inflammatory bowel disease [1].
Can other companies make Bimzelx?
Once patents expire and if no further exclusivities are in place, other pharmaceutical companies can apply to market generic versions of Bimzelx. This process involves demonstrating bioequivalence to the branded drug [2].
*
**Sources
1. https://www.bimzelx.com/
2. https://drugpatentwatch.com/
3. Information from general medical and pharmaceutical databases (not directly linked as per instructions).